Medicenna Historical Financial Ratios
| MDNA Stock | CAD 1.72 0.06 3.37% |
Medicenna Therapeutics is lately reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Medicenna Therapeutics financial condition quickly.
Medicenna |
About Medicenna Financial Ratios Analysis
Medicenna TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Medicenna Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Medicenna financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Medicenna Therapeutics history.
Medicenna Therapeutics Financial Ratios Chart
Add Fundamental
Dividend Yield
Dividend Yield is Medicenna Therapeutics Corp dividend as a percentage of Medicenna Therapeutics stock price. Medicenna Therapeutics dividend yield is a measure of Medicenna Therapeutics stock productivity, which can be interpreted as interest rate earned on an Medicenna Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Average Inventory
The average amount of inventory a company holds over a certain period, which is used to calculate inventory turnover and efficiency in managing stock levels.Most ratios from Medicenna Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Medicenna Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medicenna Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Medicenna Therapeutics' Graham Number is very stable compared to the past year. As of the 30th of November 2024, Price Book Value Ratio is likely to grow to 25.50, while Book Value Per Share is likely to drop 0.07.
| 2021 | 2022 | 2024 (projected) | Net Debt To EBITDA | 0.91 | 2.06 | 1.61 | Intangibles To Total Assets | 0.002771 | 0.001674 | 0.00283 |
Medicenna Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Medicenna Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Medicenna Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 3.18 | 6.65 | 4.3 | 1.93 | 24.28 | 25.5 | |
| Book Value Per Share | 1.13 | 0.77 | 0.38 | 0.46 | 0.0745 | 0.0708 | |
| Free Cash Flow Yield | (0.41) | (0.078) | (0.0603) | (0.26) | (0.22) | (0.13) | |
| Operating Cash Flow Per Share | (0.42) | (0.31) | (0.28) | (0.2) | (0.23) | (0.25) | |
| Pb Ratio | 3.18 | 6.65 | 4.3 | 1.93 | 24.28 | 25.5 | |
| Free Cash Flow Per Share | (0.42) | (0.31) | (0.28) | (0.2) | (0.23) | (0.25) | |
| Roic | (0.23) | (0.45) | (1.07) | 0.11 | (3.79) | (3.6) | |
| Net Income Per Share | (0.26) | (0.35) | (0.42) | 0.0239 | (0.37) | (0.38) | |
| Payables Turnover | 0.0173 | 0.0178 | 0.0227 | 0.003092 | 0.002415 | 0.002295 | |
| Cash Per Share | 0.0923 | 1.18 | 0.81 | 0.38 | 0.52 | 0.24 | |
| Pocfratio | (12.82) | (16.57) | (3.8) | (4.5) | (7.75) | (8.14) | |
| Pfcf Ratio | (12.82) | (16.57) | (3.8) | (4.5) | (7.75) | (8.14) | |
| Days Payables Outstanding | 33.0K | 42.9K | 21.1K | 20.5K | 23.6K | 43.3K | |
| Income Quality | 1.08 | 0.89 | 1.04 | 1.26 | 0.64 | 1.28 | |
| Roe | (0.23) | (0.45) | (1.09) | 0.0525 | (4.91) | (4.66) | |
| Ev To Operating Cash Flow | (10.3) | (14.59) | (2.93) | (1.85) | (6.71) | (7.04) | |
| Pe Ratio | (13.82) | (14.77) | (3.96) | 36.82 | (4.95) | (5.2) | |
| Return On Tangible Assets | (0.22) | (0.41) | (0.97) | 0.0425 | (1.33) | (1.4) | |
| Ev To Free Cash Flow | (10.3) | (14.59) | (2.93) | (1.85) | (6.71) | (7.04) | |
| Earnings Yield | (0.0724) | (0.0677) | (0.25) | 0.0272 | (0.2) | (0.21) | |
| Intangibles To Total Assets | 0.002007 | 0.00168 | 0.002771 | 0.001674 | 0.002979 | 0.00283 | |
| Net Debt To E B I T D A | 0.5 | 2.74 | 1.76 | 0.91 | 2.06 | 1.61 | |
| Current Ratio | 20.85 | 10.26 | 8.92 | 9.57 | 6.66 | 4.79 | |
| Tangible Book Value Per Share | 1.13 | 0.77 | 0.38 | 0.45 | 0.0737 | 0.07 | |
| Graham Number | 0.65 | 2.58 | 2.45 | 1.9 | 0.49 | 0.9 | |
| Shareholders Equity Per Share | 1.13 | 0.77 | 0.38 | 0.46 | 0.0745 | 0.0708 | |
| Graham Net Net | 1.12 | 0.74 | 0.35 | 0.42 | 0.0562 | 0.0534 | |
| Enterprise Value Over E B I T D A | (11.15) | (12.95) | (3.06) | (1.43) | (5.84) | (6.13) | |
| Price Earnings Ratio | (13.82) | (14.77) | (3.96) | 36.82 | (4.95) | (5.2) | |
| Price Book Value Ratio | 3.18 | 6.65 | 4.3 | 1.93 | 24.28 | 25.5 | |
| Price Earnings To Growth Ratio | (0.31) | (0.43) | (0.2) | (0.35) | 0.003003 | 0.003153 | |
| Days Of Payables Outstanding | 33.0K | 42.9K | 21.1K | 20.5K | 23.6K | 43.3K | |
| Price To Operating Cash Flows Ratio | (12.82) | (16.57) | (3.8) | (4.5) | (7.75) | (8.14) | |
| Price To Free Cash Flows Ratio | (12.82) | (16.57) | (3.8) | (4.5) | (7.75) | (8.14) | |
| Effective Tax Rate | (0.003899) | 0.006131 | (0.003056) | 1.15 | 1.04 | 1.09 | |
| Company Equity Multiplier | 1.05 | 1.11 | 1.13 | 1.24 | 3.69 | 3.87 |
Pair Trading with Medicenna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Medicenna Stock
The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.
The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medicenna Stock
Medicenna TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Medicenna Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Medicenna financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Medicenna Therapeutics history.